The PennZone

  • Home
  • Non-profit
  • Education
  • Technology
  • Construction
  • Business
  • Entertainment
  • Software
  • Sports

Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023
The PennZone/10233330

Trending...
  • Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
  • TURRENTINE: A Family Legacy United Through Music
PHILADELPHIA, June 5, 2023 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced that the Company will present at several investor conferences in June 2023. These investor conferences include:

Jefferies Global Healthcare Conference
  • Steven Kelly, President and Chief Executive Officer, will give a corporate presentation.
  • Friday, June 9 at 10:00 am EDT.
  • New York City

Baird's Biotech Discovery Series
  • Steven Kelly, President and Chief Executive Officer, and Michael Klichinsky, PhD, Co-Founder and Chief Scientific Officer, will participate in a fireside chat.
  • Wednesday, June 21 at 1:30 pm EDT.
  • Virtual

Live webcasts will be available on the Company's Investor Events webpage. A replay of the webcasts will be archived at the Company's past events section of the Investor Relations webpage for a limited time following the event.

About Carisma
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma is headquartered in Philadelphia, PA. For more information, please visit www.carismatx.com.

More on The PennZone
  • Morrisville & Cary Education Centers Honored with National Award
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Henri-Lloyd Launches Sail Free to Break Down Barriers to Sailing
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park
  • Destination Niagara Launches Game Changing Digital Magazine Redefining How Visitors Experience Niagara Falls

Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to Carisma's business, strategy, future operations, cash runway, the advancement of Carisma's product candidates and product pipeline, and clinical development of Carisma's product candidates, including expectations regarding timing of initiation and results of clinical trials, and participation by Carisma in future healthcare industry and investor conferences. The words ""anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "outlook," "plan," "project," "potential," "predict," "target," "possible," "will," "would," "could," "should," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause Carisma's actual results to differ from those contained in the forward-looking statements, see the "Risk Factors" set forth in Exhibit 99.3 to Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on March 8, 2023, as well as discussions of potential risks, uncertainties, and other important factors in Carisma's most recent filings with the Securities and Exchange Commission. Any forward-looking statements that are made in this press release speak as of the date of this press release. Carisma undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

More on The PennZone
  • Val Market is the New Frontier of the Online Marketplace
  • San Diego's newest marketing firm is boring on purpose — it's working
  • Arizona Christian Homeschools Launches Statewide Directory
  • LKPFM Corporation Canada the importance
  • Sexually Abused in a Psychiatric Hospital or Psychiatrist's or Psychologist's Office? CCHR Urges Survivors to Reach Out to It

Media Contact:
Julia Stern
(763) 350-5223
[email protected]

Investor Contact:
[email protected]

SOURCE Carisma Therapeutics Inc.
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • HomeCentris Home Health Achieves 5-Star CMS Rating
  • Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
  • Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
  • Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
  • Cango Mobility x Hikvision Announce Strategic Partnership
  • Institute of Emerging Minds Publishes Framework for Glymphatic Clearance and Cognitive Optimization
  • HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
  • Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
  • Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
  • George Martinez Completes Community Re-distribution Initiative, Returning $5,000 In Campaign Resources To Anchorage Nonprofits
  • Mister Omaha Tries The Turf At Lone Star Park
  • Andrew D. Levine Releases The Lily Network, an Indian Noir Mystery of Power, Paperwork & Murder
  • The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
  • Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
  • Joulescope JS320 Launches to Help Engineers Develop Battery-Powered Devices with Greater Confidence
  • Ghanaian Afrobeat Artist Praise Kusi Announces Upcoming EP "After 21:00" Releasing July 3, 2026
  • Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
  • TURRENTINE: A Family Legacy United Through Music
  • Save 10 Percent Off Summer Stays at KeysCaribbean Resorts

Popular on PennZone

  • Kevin Francis Design Introduces CHROMA, a Collection of Saturated Solid Color Wool Rugs - 169
  • Agape Leadership Academy Opens Nationwide Enrollment — State ESA Scholarships Cover Full Tuition for Families in 7 States
  • From Broken to Soaring Week 40
  • A Brave Little Hero with Four Paws
  • Eichelberger Performing Arts Center Announces Fall 2026 Performance Lineup
  • Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup
  • A Foundational Claim in Human Secrecy Goes Public
  • Heritage at South Brunswick Unveils Luxury Resort-Style Amenities Designed for Every Generation
  • NRE Health Institute Launches International Study Examining Motivations Behind Non-Sexual Nudity
  • Dave's Auto Services Sponsors Night of Racing at Action Track USA in Kutztown PA

Similar on PennZone

  • eCopier Solutions Surpasses 3,000 Five-Star Google Reviews and Maintains Perfect Five-Star Rating
  • Ascent Solar Technologies (N A S D A Q: ASTI): Positioned at the Intersection of the New Space Economy, Defense Innovation and Next-Generation Energy
  • Triple-Digit Growth, Stock Market Upgrade plus a Rapidly Expanding Specialty Healthcare Platform: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • AI-Powered Neuropsychiatry, FDA Regulatory Momentum, Commercial Ketamine Launch Position NRx Pharmaceuticals for Potential Breakout Growth in 2026
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Jacksonville JTB/Deerwood Park
  • LKPFM Corporation Canada the importance
  • Verbica Challenges Panetta to a Televised Debate on the Issues
  • K2 Integrity's U.S. and EMEA Teams Again Recognized in Chambers and Partners 2026 Guides
  • $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
  • The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us